AdisInsight

AdisInsight helps users to stay at the forefront of research by providing the most compelling current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available.

The user-friendly database provides easy access to expertly-written drug information, with a single search equivalent to searching across thousands of journals, conference proceedings, company websites and other published sources.

Key Facts

  • A database for drug research and development, disease treatment and decision making, based on trusted, scientifically sound data
  • Expertly reviewed, assessed and summarized by a team of scientists
  • A single search delivers results on drugs, trials, deals and safety
  • Now including curated biomarker data in drug and trial profiles

Start exploring today - visit and preview the AdisInsight Database here

We have

AdisInsight Video

  • Stay at the forefront of your research area. Rapidly assess the competitive drug landscape according to the most compelling new information
  • Focus on the most promising research paths. Identify areas where research would contribute most to filling gaps in therapy and have the greatest licensing potential
  • Improve work efficiency. Reduce the time taken to answer critical research questions with consolidated scientific and commercial data from multiple sources

An Introduction to AdisInsight

Additional information

_

Request a Trial

Find out how your institution benefits from our products

_

Tutorials & Training

_

Contact Us!

Stay up to date

_
Follow us on Twitter

Here to foster information exchange with the library community

_
Follow us on Facebook

Springer Nature's LibraryZone is a community developed to foster sharing of information with the library community. Enjoy!

_
Connect with us on LinkedIn

Connect with us on LinkedIn and stay up to date with news and development.

_
Sign up for our alerts

News, information on our forthcoming books, author content and discounts.